AELIS FARMA
Aelis Farma is a pioneer in the development of signaling specific therapeutics that target GPCRs (and more specifically the CB1 receptor which is one of the most expressed GPCRs in the brain). GPCRs are the target of most therapeutic drugs. This family of receptors has the characteristics to activate several and often opposing signaling pathways. Unfortunately, most of the drugs acting on GPCRs either block or stimulate the entire signaling activity of the receptor resulting in unwanted and sometimes unacceptable side effects.
AELIS FARMA
Social Links:
Industry:
Biotechnology Therapeutics
Founded:
2013-01-01
Address:
Bordeaux, Aquitaine, France
Country:
France
Website Url:
http://www.aelisfarma.com
Total Employee:
11+
Status:
Active
Contact:
+33 5 57 57 37 70
Email Addresses:
[email protected]
Total Funding:
26 M EUR
Technology used in webpage:
Google Maps French Server Location
Similar Organizations
Aclaris Therapeutics
Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
Apeiron Biologics
Apeiron Biologics is a biotech company that focuses on the discovery and development of novel cancer immunotherapies.
AYOXXA
AYOXXA is a biotech company commercializing innovative technology.
Iksuda Therapeutics
Iksuda Therapeutics is a biotechnology company specializing in the development of next generation biotherapeutics
Innovative Cellular Therapeutics
Innovative Cellular Therapeutics is a Shanghai-based biotechnology company engaged in research and development of cell therapy.
InventisBio
InventisBio is a clinical-stage biotech company dedicated to the research and development of innovative small-molecule drugs.
Nascent Biotech
Nascent Biotech is a biotechnology company building a portfolio of innovative therapeutic antibodies.
Versameb
Versameb is focusing on the discovery and development of innovative, next-generation RNA-based drugs.
Current Employees Featured
Founder
Stock Details
Investors List
Bpifrance
Bpifrance investment in Venture Round - Aelis Farma
National Institute on Drug Abuse (NIDA)
National Institute on Drug Abuse (NIDA) investment in Grant - Aelis Farma
Inserm Transfert Initiative
Inserm Transfert Initiative investment in Venture Round - Aelis Farma
Aelis Innovation
Aelis Innovation investment in Venture Round - Aelis Farma
Région Nouvelle-Aquitaine
Région Nouvelle-Aquitaine investment in Venture Round - Aelis Farma
fonds régionaux ACI
fonds régionaux ACI investment in Venture Round - Aelis Farma
NACO
NACO investment in Venture Round - Aelis Farma
Key Employee Changes
| Date | New article |
|---|---|
| 2024-01-17 | Aelis Farma Strengthens its Leadership Team with the Appointment of Arsène Guekam as Chief Corporate Development Officer |
Official Site Inspections
http://www.aelisfarma.com Semrush global rank: 10.62 M Semrush visits lastest month: 211
- Host name: cluster006.ovh.net
- IP address: 213.186.33.17
- Location: France
- Latitude: 48.8582
- Longitude: 2.3387
- Timezone: Europe/Paris
More informations about "Aelis Farma"
About Us - AelisFarma
In a mere 8 years we have developed two clinical drug candidates and built an innovative and efficient research platform. Our secret: a new pharmacological class, an innovative approach to drug development, and the utmost dedication of our team.See details»
Aelis Farma - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number +33 5 57 57 37 70 Aelis Farma is a pioneer in the development of signaling specific therapeutics that target GPCRs (and more specifically the CB1 receptor which is one of the most expressed GPCRs in the brain).See details»
AELIS FARMA - LinkedIn
Aelis Farma is a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases. Aelis Farma is developing a new class of drugs: Signaling Specific ...See details»
Aelis Farma (EPA:AELIS) Company Profile & Description - Stock …
Aelis Farma SA, a clinical-stage biotechnology company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders.See details»
Aelis Farma - Company Profile - Tracxn
Feb 28, 2025 Email ID: *****@aelisfarma.com; Key Metrics. Total Funding. $14M in 3 rounds. Latest Funding Round. Grant (prize money), Feb 01, 2021, $4.05M. Investors. Inserm Transfert & 9 more. Ranked. 10 th among 46 active competitors. Similar Companies. Indivior & 50 more. Exit Details. Public. Get your free copy of Aelis Farma's company profile.See details»
Aelis Farma - Overview, News & Similar companies - ZoomInfo
Aug 27, 2023 Who is Aelis Farma. AELIS FARMA is a clinical-stage biotechnology company founded in 2014 as a spin-off of the Magendie Neurocenter in Bordeaux, a leading Neuroscience institute of INSERM (French National Institute of Health and Medical Research) and University of Bordeaux. AELIS FARMA's mission is to develop a new pharmacological drug class, the …See details»
Aelis Farma - VentureRadar
Website: http://www.aelisfarma.com/ Develops innovative therapies to treat cannabis addiction and psychosis, focusing on improving mental health and well-being ...See details»
Aelis Farma - Craft
Aelis Farma is a clinical-stage biotech company that specializes in pharmacology. It aims to develop the therapeutic potential of CB1 Signaling Specific inhibitors (CB1-SSi), new molecular entities that mimicking a natural defense mechanism of the brain.See details»
Aelis Farma 2025 Company Profile: Stock Performance …
Information on stock, financials, earnings, subsidiaries, investors, and executives for Aelis Farma. Use the PitchBook Platform to explore the full profile.See details»
Org Chart Aelis Farma - The Official Board
For each of our 1,287,298 listed executives, discover their exact roles and their biographies.See details»
Investors - AelisFarma
[email protected]. NewCap. Financial communication & Investor relations. Dusan Oresansky / Aurélie Manavarere +33 (0)1 44 71 94 92. [email protected]. Media relations.See details»
Aelis Farma SA (AELIS.PA) Company Profile & Facts - Yahoo Finance
See the company profile for Aelis Farma SA (AELIS.PA) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives and their ...See details»
AELIS FARMA Information - RocketReach
Aelis Farma is a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases. Aelis Farma is developing a new class of drugs: Signaling Specific inhibitors of the CB1 receptor (CB1-SSi) of the endocannabinoid system that provide access to several therapeutic areas without available treatments.See details»
AELIS FARMA Company Overview, Contact Details & Competitors
Jul 31, 2024 Aelisfarma launched AEF0117 on Jun 14th '23. Aelis Farma, a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases, announced publication of a series of studies describing a new pharmacological class, cannabinoid receptor 1 signaling-specific inhibitors (CB1-SSi), and its first drug candidate, AEF0117, for the treatment …See details»
Aelis Farma - VentureRadar
"Aelis Farma is develop the therapeutic potential of CB1-SSi(CB1 Signaling Specific inhibitors). CB1 Signaling Specific inhibitors are a proprietary new pharmacological class never tested in humans before that open a new frontier in pharmacology.See details»
Aelis Farma Reports Its 2024 Annual Financial Results and …
9 hours ago BORDEAUX, France, April 01, 2025--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for ...See details»
Aelis Farma Reports Its 2024 Annual Financial Results and …
10 hours ago Pier Vincenzo Piazza, CEO of Aelis Farma, stated: “The year 2024 was marked by significant advances in the clinical developments of our two drug candidates, AEF0117 and AEF0217, confirming the therapeutic activity of CB 1-SSi in humans.For AEF0117, although the Phase 2b study in cannabis addiction (CUD) did not meet its primary endpoint, the preliminary …See details»
Home - AelisFarma
Aelis Farma is a biotechnology company specialized in the treatment of brain disordersSee details»
Aelis Farma, a pioneer of a new generation of drugs for the brain
Feb 2, 2022 Regulatory News: Not to be distributed, directly or indirectly, in the United States of America, Canada, Australia, Japan or South Africa. Aelis FarmaSee details»
Aelis Farma Reports Its 2024 Annual Financial Results and …
1 day ago Simplified income statement 1 (in €K). 2024. 2023. Revenue from ordinary activities 5,562 12,358 Research and development costs (9,942) (16,212) General and administrative expensesSee details»